238 related articles for article (PubMed ID: 34162985)
1. TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.
Yu X; James S; Felce JH; Kellermayer B; Johnston DA; Chan HTC; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; Watanabe Y; Crispin M; French RR; Duriez PJ; Douglas LR; Glennie MJ; Cragg MS
Commun Biol; 2021 Jun; 4(1):772. PubMed ID: 34162985
[TBL] [Abstract][Full Text] [Related]
2. Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors.
Jhajj HS; Schardt JS; Khalasawi N; Yao EL; Lwo TS; Kwon NY; O'Meara RL; Desai AA; Tessier PM
Cell Chem Biol; 2024 May; 31(5):944-954.e5. PubMed ID: 38653243
[TBL] [Abstract][Full Text] [Related]
3. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
4. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X; Chan HTC; Fisher H; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; French RR; Duriez PJ; Douglas LR; English V; Verbeek JS; White AL; Tews I; Glennie MJ; Cragg MS
Cancer Cell; 2020 Jun; 37(6):850-866.e7. PubMed ID: 32442402
[TBL] [Abstract][Full Text] [Related]
5. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis.
Sun Y; Lin X; Chen HM; Wu Q; Subudhi SK; Chen L; Fu YX
J Immunol; 2002 Feb; 168(3):1457-65. PubMed ID: 11801689
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
7. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Yu X; Chan HTC; Orr CM; Dadas O; Booth SG; Dahal LN; Penfold CA; O'Brien L; Mockridge CI; French RR; Duriez P; Douglas LR; Pearson AR; Cragg MS; Tews I; Glennie MJ; White AL
Cancer Cell; 2018 Apr; 33(4):664-675.e4. PubMed ID: 29576376
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
9. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
10. Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily.
Niwa T; Kasuya Y; Suzuki Y; Ichikawa K; Yoshida H; Kurimoto A; Tanaka K; Morita K
Mol Pharm; 2018 Sep; 15(9):3729-3740. PubMed ID: 29648839
[TBL] [Abstract][Full Text] [Related]
11. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity.
Zhang P; Tu GH; Wei J; Santiago P; Larrabee LR; Liao-Chan S; Mistry T; Chu ML; Sai T; Lindquist K; Long H; Chaparro-Riggers J; Salek-Ardakani S; Yeung YA
Cell Rep; 2019 Jun; 27(11):3117-3123.e5. PubMed ID: 31189099
[TBL] [Abstract][Full Text] [Related]
12. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
13. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
14. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.
Heckel F; Turaj AH; Fisher H; Chan HTC; Marshall MJE; Dadas O; Penfold CA; Inzhelevskaya T; Mockridge CI; Alvarado D; Tews I; Keler T; Beers SA; Cragg MS; Lim SH
Commun Biol; 2022 Mar; 5(1):229. PubMed ID: 35288635
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
16. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE; Kovacsovics-Bankowski M; Weinberg AD
Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB.
Arch RH; Thompson CB
Mol Cell Biol; 1998 Jan; 18(1):558-65. PubMed ID: 9418902
[TBL] [Abstract][Full Text] [Related]
18. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
19. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.
Ju SA; Lee SC; Kwon TH; Heo SK; Park SM; Paek HN; Suh JH; Cho HR; Kwon B; Kwon BS; Kim BS
Immunol Cell Biol; 2005 Aug; 83(4):344-51. PubMed ID: 16033529
[TBL] [Abstract][Full Text] [Related]
20. Co-stimulation agonists as a new immunotherapy for autoimmune diseases.
Sun Y; Subudhi SK; Fu YX
Trends Mol Med; 2003 Nov; 9(11):483-9. PubMed ID: 14604826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
